{"id":32301,"date":"2025-04-23T17:14:15","date_gmt":"2025-04-23T09:14:15","guid":{"rendered":"https:\/\/flcube.com\/?p=32301"},"modified":"2025-04-23T17:14:16","modified_gmt":"2025-04-23T09:14:16","slug":"grand-pharma-secures-nmpa-approval-for-fluticasone-nasal-spray","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32301","title":{"rendered":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray"},"content":{"rendered":"\n<p>China-based Grand Pharmaceutical Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">HKG: 0512<\/a>) has obtained marketing authorization from China&#8217;s National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>)\u00a0 branded drug Flonase and represents China&#8217;s first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).<\/p>\n\n\n\n<p><strong>Product and Market Context<\/strong><br>Fluticasone propionate, a synthetic glucocorticoid, is indicated for the treatment of nasal congestion related to allergic rhinitis. In China&#8217;s nasal corticosteroid spray market, which reached RMB 3.54 billion (USD 486 million) in 2023, the three dominant products\u2014mometasone, budesonide, and fluticasone\u2014collectively captured a 65% market share, equivalent to RMB 2.3 billion (USD 315 million). Grand Pharmaceutical&#8217;s entry into this market underscores its commitment to providing accessible and effective treatment options for patients with allergic rhinitis.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025042200710_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025042200710_c.\"><\/object><a id=\"wp-block-file--media-f3d382b5-5622-4af3-a043-ec4b46b6af89\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025042200710_c.pdf\">2025042200710_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025042200710_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f3d382b5-5622-4af3-a043-ec4b46b6af89\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32302,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[42,278,683,184,1184,914,15],"class_list":["post-32301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-first-mover-generic","tag-glaxosmithkline","tag-grand-pharmaceutical","tag-gsk","tag-hkg-0512","tag-nyse-gsk","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China&#039;s National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 branded drug Flonase and represents China&#039;s first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32301\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray\" \/>\n<meta property=\"og:description\" content=\"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China&#039;s National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 branded drug Flonase and represents China&#039;s first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32301\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T09:14:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T09:14:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray\",\"datePublished\":\"2025-04-23T09:14:15+00:00\",\"dateModified\":\"2025-04-23T09:14:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301\"},\"wordCount\":162,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2312.webp\",\"keywords\":[\"First-mover generic\",\"GlaxoSmithKline\",\"Grand Pharmaceutical\",\"GSK\",\"HKG: 0512\",\"NYSE: GSK\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32301#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32301\",\"name\":\"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2312.webp\",\"datePublished\":\"2025-04-23T09:14:15+00:00\",\"dateModified\":\"2025-04-23T09:14:16+00:00\",\"description\":\"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China's National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 branded drug Flonase and represents China's first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32301\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2312.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2312.webp\",\"width\":1080,\"height\":608,\"caption\":\"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32301#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China's National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 branded drug Flonase and represents China's first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32301","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray","og_description":"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China's National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 branded drug Flonase and represents China's first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).","og_url":"https:\/\/flcube.com\/?p=32301","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-23T09:14:15+00:00","article_modified_time":"2025-04-23T09:14:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32301#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32301"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray","datePublished":"2025-04-23T09:14:15+00:00","dateModified":"2025-04-23T09:14:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32301"},"wordCount":162,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32301#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp","keywords":["First-mover generic","GlaxoSmithKline","Grand Pharmaceutical","GSK","HKG: 0512","NYSE: GSK","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32301#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32301","url":"https:\/\/flcube.com\/?p=32301","name":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32301#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32301#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp","datePublished":"2025-04-23T09:14:15+00:00","dateModified":"2025-04-23T09:14:16+00:00","description":"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China's National Medical Products Administration (NMPA) for its generic fluticasone propionate nasal spray. This product is a bioequivalent version of GlaxoSmithKline (GSK, NYSE: GSK)\u00a0 branded drug Flonase and represents China's first approved generic of this corticosteroid nasal spray. It has been concurrently listed in both the National Reimbursement Drug List (NRDL) and National Essential Drugs List (NEDL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32301#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32301"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32301#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp","width":1080,"height":608,"caption":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32301#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2312.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32301"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32301\/revisions"}],"predecessor-version":[{"id":32304,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32301\/revisions\/32304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32302"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}